AFFYMAX MAKES "REAL PROGRESS"

Affymax is a stock in the right place at the right time with dedicated management and a visionary director, say analysts Amy Bernhard Berler and Mara Goldstein from Alex Brown & Sons.

The analysts note that despite few conventional drug development benchmarks, Affymax appears to be making real progress in developing its technologies and creating a strong share value.

For 1993, the company is expected to close one or more collaborative partnerships that should signify progress by retaining more value than previous collaborations in financial structure, target molecule definition, or retention of marketing rights.